Genscript Biotech Corporation

SEHK:1548 Stock Report

Market Cap: HK$25.7b

Genscript Biotech Valuation

Is 1548 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1548 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1548 (HK$12.08) is trading above our estimate of fair value (HK$11.9)

Significantly Below Fair Value: 1548 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1548?

Other financial metrics that can be useful for relative valuation.

1548 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3x
Enterprise Value/EBITDA-10.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 1548's PS Ratio compare to its peers?

The above table shows the PS ratio for 1548 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.7x
2268 WuXi XDC Cayman
9.2x25.9%HK$28.0b
2269 WuXi Biologics (Cayman)
3.8x10.7%HK$70.1b
1873 Viva Biotech Holdings
1xn/aHK$2.1b
1521 Frontage Holdings
0.7x15.9%HK$1.5b
1548 Genscript Biotech
3.3x39.9%HK$25.7b

Price-To-Sales vs Peers: 1548 is good value based on its Price-To-Sales Ratio (3.3x) compared to the peer average (3.7x).


Price to Earnings Ratio vs Industry

How does 1548's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a50.5%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a50.5%
n/an/an/a
No more companies

Price-To-Sales vs Industry: 1548 is good value based on its Price-To-Sales Ratio (3.3x) compared to the Asian Life Sciences industry average (4.3x).


Price to Sales Ratio vs Fair Ratio

What is 1548's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1548 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.3x
Fair PS Ratio10.2x

Price-To-Sales vs Fair Ratio: 1548 is good value based on its Price-To-Sales Ratio (3.3x) compared to the estimated Fair Price-To-Sales Ratio (10.2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1548 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$12.08
HK$23.28
+92.8%
18.7%HK$29.02HK$16.00n/a10
Oct ’25HK$13.94
HK$23.56
+69.0%
18.8%HK$29.12HK$16.00n/a10
Sep ’25HK$11.82
HK$23.56
+99.3%
18.8%HK$29.12HK$16.00n/a10
Aug ’25HK$12.16
HK$24.14
+98.5%
27.6%HK$30.94HK$10.60n/a9
Jul ’25HK$8.32
HK$25.03
+200.9%
27.4%HK$33.03HK$10.60n/a10
Jun ’25HK$10.00
HK$27.73
+177.3%
17.7%HK$32.98HK$16.00n/a10
May ’25HK$11.64
HK$28.85
+147.8%
10.6%HK$33.06HK$23.00n/a10
Apr ’25HK$14.50
HK$28.85
+98.9%
10.6%HK$33.06HK$23.00n/a10
Mar ’25HK$15.50
HK$30.55
+97.1%
5.4%HK$33.03HK$27.02n/a10
Feb ’25HK$14.10
HK$30.55
+116.7%
5.4%HK$33.03HK$27.02n/a10
Jan ’25HK$19.86
HK$30.95
+55.9%
6.7%HK$34.73HK$27.00n/a10
Dec ’24HK$21.50
HK$30.90
+43.7%
6.7%HK$34.67HK$26.96n/a10
Nov ’24HK$22.85
HK$29.78
+30.3%
12.3%HK$34.81HK$23.94n/a9
Oct ’24HK$20.65
HK$28.65
+38.8%
17.0%HK$34.83HK$18.45HK$13.9410
Sep ’24HK$18.38
HK$28.47
+54.9%
16.8%HK$34.90HK$18.49HK$11.8210
Aug ’24HK$20.30
HK$29.19
+43.8%
19.1%HK$36.81HK$18.39HK$12.1610
Jul ’24HK$17.60
HK$29.16
+65.7%
19.0%HK$36.96HK$18.47HK$8.3210
Jun ’24HK$17.54
HK$28.51
+62.5%
21.0%HK$35.01HK$18.46HK$10.006
May ’24HK$20.60
HK$27.98
+35.8%
22.8%HK$35.10HK$18.50HK$11.645
Apr ’24HK$16.80
HK$31.58
+87.9%
21.3%HK$41.00HK$20.50HK$14.505
Mar ’24HK$22.75
HK$31.61
+38.9%
21.3%HK$41.00HK$20.50HK$15.505
Feb ’24HK$28.20
HK$31.72
+12.5%
22.0%HK$41.88HK$20.44HK$14.105
Jan ’24HK$24.85
HK$30.84
+24.1%
24.6%HK$41.76HK$20.38HK$19.864
Dec ’23HK$19.58
HK$30.48
+55.7%
24.9%HK$41.78HK$20.39HK$21.504
Nov ’23HK$20.50
HK$30.80
+50.3%
28.6%HK$42.00HK$20.50HK$22.853
Oct ’23HK$17.16
HK$35.10
+104.5%
27.1%HK$45.59HK$20.50HK$20.655

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies